% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@MISC{Lohmann:908209,
      author       = {Lohmann, P. and Stavrinou, P. and Lipke, K. and Bauer, E.
                      K. and Ceccon, G. and Werner, J. and Fink, G. R. and Shah,
                      N. J. and Langen, K. and Galldiks, N.},
      title        = {{P}14.32 {S}patial discrepancies between {FET} {PET} and
                      conventional {MRI} in patients with newly diagnosed
                      glioblastoma},
      issn         = {1523-5866},
      reportid     = {FZJ-2022-02460},
      year         = {2019},
      abstract     = {AbstractBACKGROUNDIn patients with glioblastoma, the tissue
                      showing contrast enhancement (CE) in MRI is usually the
                      target for resection or radiotherapy. However, the solid
                      tumor mass typically extends beyond the area of CE. Amino
                      acid PET can detect tumor parts that show no CE. We
                      systematically investigated tumor volumes delineated by
                      amino acid PET and MRI in newly diagnosed, untreated
                      glioblastoma patients.MATERIAL AND METHODSPreoperatively, 50
                      patients with subsequently neuropathologically confirmed
                      glioblastoma underwent O-(2-[18F]-fluoroethyl)-L-tyrosine
                      (FET) PET, fluid-attenuated inversion recovery (FLAIR), and
                      CE MRI. Areas of CE were manually delineated. FET PET tumor
                      volumes were segmented using a tumor-to-brain ratio ≥ 1.6.
                      The percentage of overlapping volumes (OV), as well as Dice
                      and Jaccard spatial similarity coefficients (DSC; JSC), were
                      calculated. FLAIR images were evaluated visually.RESULTSIn
                      $86\%$ of patients (n = 43), the FET PET tumor volume was
                      significantly larger than the volume of CE (21.5 ± 14.3 mL
                      vs. 9.4 ± 11.3 mL; P < 0.001). Forty patients $(80\%)$
                      showed both an increased uptake of FET and CE. In these 40
                      patients, the spatial similarity between FET and CE was low
                      (mean DSC, 0.39 ± 0.21; mean JSC, 0.26 ± 0.16). Ten
                      patients $(20\%)$ showed no CE, and one of these patients
                      showed no FET uptake. In $10\%$ of patients (n = 5),
                      increased FET uptake was present outside of areas of FLAIR
                      hyperintensity.CONCLUSIONOur results show that the
                      metabolically active tumor volume delineated by FET PET is
                      significantly larger than tumor volume delineated by CE. The
                      data strongly suggest that the information derived from FET
                      PET should be integrated into the management of newly
                      diagnosed glioblastoma patients.FUNDINGThis work was
                      supported by the Wilhelm-Sander Stiftung, Germany},
      cin          = {INM-4 / INM-11 / JARA-BRAIN},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-4-20090406 / I:(DE-Juel1)INM-11-20170113 /
                      I:(DE-Juel1)VDB1046},
      pnm          = {5253 - Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)4},
      UT           = {WOS:000493085900269},
      doi          = {10.1093/neuonc/noz126.267},
      url          = {https://juser.fz-juelich.de/record/908209},
}